Synonyms: compound 9 [PMID: 38687966] | Example 95 [US20220257563] | N-(Methoxycarbonyl)-3-methyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-L-prolinamide | PF-07817883 | PF07817883
Compound class:
Synthetic organic
Comment: PF-07817883 is an oral SARS-CoV-2 3CL (main) protease (Mpro) inhibitor. The compound and its use are claimed in patent US20220257563A1 [2]. We matched this chemical structure to the INN ibuzatrelvir from proposed INN list 129, and its formal disclosure in [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
PF-07817883 was advanced to clinical evaluations, to determine safety and efficacy as a treatment for SARS-CoV-2 infection (COVID-19). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05580003 | A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People | Phase 1 Interventional | Pfizer | ||
NCT05799495 | A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized | Phase 2 Interventional | Pfizer |